Industry
Biotechnology
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
Loading...
Open
55.00
Mkt cap
2.4B
Volume
141K
High
55.97
P/E Ratio
-19.75
52-wk high
59.75
Low
53.41
Div yield
N/A
52-wk low
26.38
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
August 07, 2024 | 8:34 pm
Portfolio Pulse from Benzinga Newsdesk
July 31, 2024 | 3:54 pm
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 12:26 pm
Portfolio Pulse from Piero Cingari
May 29, 2024 | 9:56 pm
Portfolio Pulse from Benzinga Newsdesk
May 22, 2024 | 8:23 pm
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 12:36 pm
Portfolio Pulse from Benzinga Newsdesk
May 10, 2024 | 9:19 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 9:19 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.